Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Bullboard Posts
Comment by hcdtradingon Dec 21, 2017 1:16pm
117 Views
Post# 27207152

RE:RE:RE:Did anybody get some reply?

RE:RE:RE:Did anybody get some reply?While we had been making considerable progress, we were unable to conclude a definitive agreement in the timeline expected. In light of the challenges faced, we have accelerated the clinical development strategy. A successful clinical trial will yield compelling scientific data which will further increase the value and marketability of the compound.

Sounds to me like they are starting from scratch and the ones they were trying to make a deal with thought the value they were asking was too high.  Or they told them to do clinicals and maybe we will pay the price you are wanting if they turn out well.  The words highlighted say it all,  new strategy and marketability. those words mean they are far away from a deal for 1067.  Not sure how anyone reads this any different.
Bullboard Posts